Leader in Microencapsulation Technology

TAGRA INNOVATIVE WHITENING SOLUTIONS Clinically proven for skin lightening

( Pag

e 2

)

Global trends reflect a rising demand for perfect skin complexion, specifically in the area of skin lightening/brightening products. Tagra’s unique whitening range consists of three main encapsulated ingredients that work harmoniously in order to achieve an immediate and long term whitening effect.

Tagra’s Whitening Range

TAGRAVIT™C1 Spherical microcapsules, 35µm, loaded with 25% Ascorbyl Tetraisopalmitate. Tagravit™C1 Microcapsules are based on Tagra’s unique Release on Demand™ (RND™) (Figure.1). Microencapsulation technology enables optimal isolation and stabilization of the Ascorbyl Tetraisopalmitate by protecting it from oxidation and degradation thus ensuring both its stability and efficient delivery. Ascorbyl Tetraisopalmitate is a lypophilic derivative of Vitamin C which exhibits excellent percutaneous, absorption and effectively converts into free Vitamin C. Vitamin C superior whitening activity is attributed to its ability to inhibit intracellular activity of Tyrosinase and melanogenesis and to suppress transporting of melanin to the upper dermis (keratinocytes). Other benefits of Tagravit™C1 include: UV protection: anti-oxidantion, anti-aging, anti-pigmentation and anti-acne.

TAGRANAT™LICORICE1Spherical microcapsules, 40µm loaded with 10% Licorice (Glycyrrhiza Glabra) root extract (equivalent to 4% of pure Glabridin). Tagranat™Licorice1 microcapsules are based on Tagra’s unique Release on Demand™ (RND™) (Figure.1) microencapsulation technology, which masks its strong color and odor. Tagra’s microencapsulation technology allows Licorice extract to be converted into free flowing powder thus, avoiding agglomeration. The effective delivery system ensures protection from oxidation, degradation, incompatibilities and guarantees both its stability and efficient delivery. Glabridin’s whitening activity is attributed to its ability to prevent UVB-induced pigmentation and inhibits melanin biosynthesis by preventing Tyrosinase activity of melanocytes. Other benefits of Tagranat™Licorice1 include: anti-inflammatory, anti-oxidation, acne treatment, anti-aging and age spots reduction.

Tagra Innovative Whitening Solutions Clinically proven for skin lightening

HO

HO

HO OHH

O O Vitamin C

( Page 3 )

CAMELEON™ WHITE Spherical microcapsules, 70µm, loaded with 90% pigmentary grade TiO2. Cameleon™White microcapsules are based on Tagra’s unique Release on Demand™ (RND™) Technology (Figure.1). Color is revealed upon application by simply rubbing the formulation onto skin. Cameleon™White provide an immediate striking white appearance, while delivering lightening active ingredients.

TAGRA RND™ RELEASE ON DEMAND UNIQUE TECHNOLOGYTagra’s whitening concept is based on the unique patented RND™ Release on Demand Technology. Active ingredients and pigments are released upon mechanical pressure, such as a rubbing action. Upon application, the polymeric shell collapses and the microcapsules fracture, releasing the encapsulated ingredient (Figure.1). Microcapsules breakdown to invisible particles, but still retain the payload to deliver over time.

B

A

Figure 1. A. SEM micrograph of Ascorbyl Tetraisopalmitate microcapsules, Tagravit™C1. B. SEM observation demonstrating the Release on Demand™ (RND™) technology of Ascorbyl Tetraisopalmitate on the skin from Tagravit™C1 by applying mechanical pressure. Magnification: (1K / bar - 10 µm)

( Pag

e 4

)

TAGRAVIT™C1 STABILITY TESTTagravit™C1 microcapsule shell is made of a single layer polymeric, which provides optimal isolation of the Ascorbyl Tetraisopalmitate and prevents incompatibilities with other ingredients composing the formulation. The Ascorbyl Tetraisopalmitate remains stable and potent, due to its encapsulation and is released by RND™ technology. The Tagravit™C1 microcapsules significantly increase Ascorbyl Tetraisopalmitate’s stability (Fig. 2) and therefore, improve the end product’s stability and efficiency.

REMARKABLE RESULTS ON ASIAN SKIN AFTER 3 MONTHS OF TREATMENTThe lightening effect on the skin, containing 5% w/w Tagravit™C1 was evaluated on 12 Asian females and Tagranat™Licorice1 on 13 Asian females (aged 35-60 years old), within a period of 2-3 months of application, twice daily on the face and outer forearms. Non-treated areas, before treatments, consider as a baseline (t0w). Chromameter was used for measuring the skin color and Mexameter to measure Melanin content.

Chromameter MeasurementsL*, a*, b* parameters were measured by chromametry and Individual Typological Angle (ITA°) was calculated : ITA°=arctg [(L*-50)/b*] x (180/π).

The luminance L* represents the skin’s relative brightness from total darkness (L*=0) to absolute white (L*=100) and ITA° characterizes the skin color. L* and ITA° are considered for the assessment of the lightening effect: the lighter the skin, the higher the L* and ITA° values.

Figure 2. Stability of Tagravit™ C1 microcapsules compared to free Ascorbyl Tetraisopalmitate incorporated in topical O/W formulation after 16 weeks storage at 40°C. Data are represented as mean Ascorbyl Tetraisopalmitate content (% of initial, n= 3).

Cont

ent o

f VCI

P (%

of in

itial

)Time (weeks)

TagravitTM C1

Free VCIP100

75

50

25

00 4w 8w 13w 16w

( Page 5 )

After 2 months (t8w) of face treatment, applying 5% Tagravit™C1 or 2% Tagranat™ L1, L*-value increased significantly by 2.07 and 2.46 , respectively (Fig.3). Results were enhanced after three months (t12w) of treatment, L*-value increased significantly by 2. 46 and 2.66, respectively (Fig.3).

After 2 months (t8w) of face treatment, applying 5% Tagravit™C1 or 2% Tagranat™L1, ITA°-value increased significantly by 5.73 and 6.1, respectively (Fig.3). Results were enhanced after three months, ITA°-value increased significantly by 7.45 and 7.60, respectively (Fig.4).

Tagranat L1 Tagravit C1

ITA

° Va

lue t8w

t0w

t12w

353025201510

50

Figure 3. Mean L*- value (skin brightness parameter) obtained from the face area treated with O/W formulation contains 5% w/w Tagravit™C1 or 2 % w/w Tagranat™L1 for 8 and 12 weeks (n=12, n=13, respectively). *, P<0.05 as compared to t0w (baseline).

Figure 4. Mean ITA° - value (whitening efficacy parameter) obtained from the face area treated with O/W formulations contain 5% w/w Tagravit ™C1 or 2% w/w Tagranat™L1, for two and three month (n=12, n=13, respectively). *, P<0.05 as compared to t0w (baseline)

L*

t8w

t0w

t12w

61.561

60.560

59.559

58.558

57.5Tagravit C1

**

**

Tagranat L1

****

( Pag

e 6

)

Mexameter Measurements Tagravit™C1 (5% w/w) lightening action on the skin, was evaluated by measuring the Melanin content in the skin. Melanin is largely responsible for the skin color. Melanin value, decreased significantly in the facial area by 18.9 after 2 months and by 21.8 after 3 months, compared with the baseline (Figure.5). Melanin value, decreased significantly in the outer forearm by 37.4, 44.8, compared with the baseline, after application twice daily on face and outer forearms after eight and twelve weeks, respectively (Fig.5).

The results of the clinical study clearly show that the encapsulation process preserves the dermatological activity of Vitamin C as a whitening agent.

Tagranat™L1 lightening action on the skin was evaluated by measuring Melanin content in the skin. Melanin value, decreased significantly in the facial area and forearms by 24.7, 31.5 and 38.6, 50.6, compared with baseline, after application twice daily on face and outer forearms, eight and twelve weeks, respectively (Fig.6).

The results of the clinical study clearly show that the encapsulation process preserves the dermatological activity of Glabridin as a whitening agent.

300

200

100

0Mel

anin

con

tent

t8w

t0w

t12w

Face

Figure 5. Mean melanin value obtained from the outer forearm and facial area treated with O/W formulation contains 5% w/w Tagravit™C1 for 12 weeks (n=12). * P<0.05 as compared to t0w (baseline)

Outer Forearm

t8w

t0w

t12w

Face

Mel

anin

con

tent

Outer Forearm

300250200150100

500

Figure 6. Mean melanin value obtained from the outer forearm and facial area treated with O/W formulation contains 2% w/w Tagranat™L1 for 8, 12 weeks (n=13). *,P<0.05 as compared to t0w (baseline)

Outer Forearm

**

****

**

( Page 7 )

Self-AssessmentAfter 3 months of applying a cream containing 2% Tagranat™Licorice1 or 5% Tagravit™C1 twice daily, the tested group’s

Results show:

Tagranat™ Licorice

Tagravit™ C1

skin Lighter/ Whiter 84.6% 75.0%

reduce yellowish and dark dull skin 91.7% 69.2%

improve skin brightness and fairness 75% 69.2%

reduce uneven skin visibly 75% 76.9%

improve skin complexion 53.8% 75.0%

willing to introduce the product to their family & friends

84.6% 83.3%

INCI’s:

Cameleon™White Titanium Dioxide (and) Acrylates/Ammonium Methacrylate copolymer.

Tagravit™C1 Ascorbyl Tetraisopalmitate & Polymethyl Methacrylate.

Tagrant™Licorice1 Glycyrrhiza Glabra (Licorice) Root Extract (and) Polymethyl Methacrylate (and) BHT (and) Tricaprylin.

For more information and samples please contact: info@tagra.com

SKIN VISIBILITY IS LIGHTER AND MORE UNIFIED WHILE ENHANCING SKIN COMPLEXIONTagra’s innovative whitening line appears in the form of non-agglomer-ated powders, which are easily incorpo-rated into finished formulations, during the last step of its preparation. These products are compatible with all types of cosmetics formulations.

Tagra Biotechnologies Ltd. Tel-Hai Industrial Park, Northern Galilee 1220900, Israel | www.tagra.com